Merck's most recent trend suggests a bullish bias. One trading opportunity on Merck is a Bull Put Spread using a strike $58.50 short put and a strike $53.50 long put offers a potential 13.9% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $58.50 by expiration. The full premium credit of $0.61 would be kept by the premium seller. The risk of $4.39 would be incurred if the stock dropped below the $53.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Merck is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Merck is bullish.
The RSI indicator is at 78.05 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Merck
Merck 4-week hep C regimen with Gilead's Sovaldi comes up short
Mon, 10 Nov 2014 00:03:15 GMT
Merck’s Four-Week Hepatitis C Regimen Fails to Top Gilead
Sun, 09 Nov 2014 23:53:20 GMT
Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®
Sun, 09 Nov 2014 23:53:00 GMT
Business Wire – Merck , known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment …
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
Sun, 09 Nov 2014 23:23:00 GMT
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
Fri, 07 Nov 2014 16:00:00 GMT
PR Newswire – WHITEHOUSE STATION, N.J., Nov. 7, 2014 /PRNewswire/ — Merck (MRK), known as MSD outside the United States and Canada, is teaming with celebrity chef and cookbook author Leticia Moreinos Schwartz on Desafiando La Diabetes: Logra Tus Metas, an educational program encouraging Hispanics with type 2 diabetes to achieve better control of their blood sugar — a key treatment goal to help reduce the risk of serious health problems. Hispanics in the United States are at a higher risk for developing type 2 diabetes than non-Hispanic white adults, and it is the fifth leading cause of death within the Hispanic community. Chef Leticia, who has a family history of type 2 diabetes, will visit select cities to cook up some of her favorite diabetes-friendly Latin recipes, urge Hispanics to know their A1C (average blood sugar level over the past two to three months), and work with their doctors to set and attain their own A1C goal.
Also on Market Tamer…
Follow Us on Facebook